Participated · Equity · Aug 2026

Network Bio focuses on linking fragmented biorepositories at major academic medical centers to provide trusted, permissioned access to biological samples (blood, tissue), genomic information, and longitudinal clinical data. The company’s work centers on interoperability, standardization, consent management, governance, and privacy-preserving computation to make these assets usable for research, drug discovery, diagnostics, and AI development. Its stated plans include creating federated biological data networks and consent and identity infrastructure that hospitals will trust. Financially, the company recently raised $50 million to advance this infrastructure; the article does not detail other financial metrics, revenue, users, or prior funding rounds. The effort is framed as building an important healthcare AI infrastructure layer by enabling access to high-quality biological samples connected to clinical outcomes.

Participated · Series B · Jun 2026

Connie Health is an AI-native Medicare navigation platform that combines proprietary technology with a network of local trusted agents to help seniors find and enroll in appropriate Medicare coverage. The company powers agent workflows and consumer guidance with AI and intelligent automation and positions itself as a strategic partner to Accountable Care Organizations, health systems, and risk-bearing providers. Connie recently completed its 10th acquisition, integrating Clearlink's Medicare business, and announced a $40 million Series B, bringing total funding to date to $85 million. It plans to use capital to expand its agent network, pursue additional M&A, advance its AI-driven platform, and deepen integrations with value-based care partners. Connie is headquartered in Boston and emphasizes preserving local, human-centered support while scaling through technology.

Participated · Series B · Apr 2026

Beacon Biosignals develops FDA-cleared wearable EEG technology combined with advanced AI to capture and analyze real-world neural data. Its platform provides clinicians and biopharma partners with objective measures of brain function intended to accelerate research, improve diagnostics and guide new treatments across neurology, psychiatry and sleep medicine. The company is led by CEO Jacob Donoghue and is based in Boston, MA. Beacon reported cumulative funding of over $132M following the Series B extension. The company plans to use the new proceeds to further scale at-home EEG deployments and expand its analytics capabilities to support diagnostics, clinical trials and precision medicine.

Participated · Series A · Dec 2025

Radial Health develops the clinical infrastructure, reimbursement tools, and an AI-guided decision support platform to support delivery of Brain Medicine treatments, including non-invasive therapies such as Deep TMS. The company operates as a management services organization for a network of Brain Medicine clinics and is building a national platform for advanced mental health care. Radial is using capital from its Series A syndicate to expand its clinical footprint, strengthen its technology platform, and increase patient access to evidence-based Brain Medicine treatments. The financing is also intended to support Radial's exploration of M&A opportunities. Investors in the company’s recent financing include BrainsWay, General Catalyst, Floating Point Capital, Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, and Diede van Lamoen.

Led · Equity · Jul 2025

Synfini operates an AI Cloud Foundry platform that merges artificial intelligence, automated synthesis, and iterative molecular design to accelerate discovery and synthesis of small molecules. The platform integrates target selection, compound design, reaction route prediction, and synthesis into a single workflow that shortens iteration cycles and reduces costs. By combining physical and virtual chemistry, Synfini produces novel, optimized compounds more rapidly than traditional early discovery processes. Since spinning out from SRI in 2023, the company has confirmed its approach through early traction and strategic partnerships. Synfini will use recent funding to expand its software and automated lab capabilities, hire additional scientific and engineering staff, and deepen commercial partnerships. The company has raised a total of $53 million to date, including the latest $8.9 million expansion and a mix of venture investments and non-dilutive grants.